Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.43 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.41 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.41 |
| ▸ | MPL | P40238 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.40 |
| ▸ | ALKBH2 | Q6NS38 | 1/20 | 0.39 |
| ▸ | ALKBH3 | Q96Q83 | 1/20 | 0.39 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | TTR | P02766 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9909206 | 0.86 | HTT (0.48) | MPLRORCMRGPRX4ESR1 | |
| SCHEMBL9909229 | 0.85 | HTR5A (0.46) | CYP2C9 | |
| SCHEMBL9907394 | 0.83 | CSNK2A2 (0.43) | IP6K1IP6K3IP6K2MRGPRX4 | |
| SCHEMBL9907371 | 0.83 | KMO (0.53) | KMORORCMRGPRX4CYP2C9TTR | |
| SCHEMBL9909223 | 0.79 | KMO (0.52) | KMOSLC22A12IP6K1IP6K3IP6K2 | |
| SCHEMBL9909220 | 0.79 | KIF11 (0.50) | KMOSLC22A12IP6K1IP6K3IP6K2 | |
| SCHEMBL9925388 | 0.78 | CSNK2A2 (0.41) | SLC22A12IP6K1IP6K3IP6K2FTO | |
| SCHEMBL9907470 | 0.78 | CSNK2A2 (0.41) | KMOSLC22A12IP6K1IP6K3IP6K2 | |
| SCHEMBL9907390 | 0.77 | PTGDR2 (0.45) | SLC22A12IP6K1IP6K3IP6K2ALKBH2 | |
| SCHEMBL14106102 | 0.77 | MPL (0.43) | KMOMPLSMN1; SMN2PLA2G2DTTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853242-B2 | Nitrogenous-ring acylguanidine derivative | ASTELLAS PHARMA INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-07 | — | — | US | disclosed |
| WO-2011016504-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | アステラス製薬株式会社 (JP) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142727-A1 | NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | KMO 559/4885SLC22A12 1751/4885IP6K1 4169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.